Form 4: Lixte Biotechnology Director Stephen Forman Receives Stock Options in Lieu of Cash Compensation
SEC Form 4
Director Stephen Forman of Lixte Biotechnology Holdings, Inc. was granted 3,030 stock options on January 20, 2025, in lieu of quarterly cash compensation.
Summary
- Stephen Forman, a director at Lixte Biotechnology Holdings, Inc., received 3,030 stock options on January 20, 2025.
- These options were granted in place of his quarterly cash compensation under the Board Compensation Plan.
- The options vest immediately and have an exercise price of $2.33 per share.
- The options expire on January 20, 2030.
- The document also lists other previously granted options and warrants held by Mr. Forman, some directly and some indirectly through a living trust.
Sentiment
Score: 7
Explanation: The document reflects a routine compensation practice, which is generally positive for aligning director and shareholder interests. There are no negative implications.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- The immediate vesting of the options provides an immediate incentive for the director.
Management Comments
- The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Industry Context
This is a standard practice for compensating board members, particularly in smaller or growth-oriented companies where equity-based compensation is often used to conserve cash and align interests.
Comparison to Industry Standards
- Granting stock options to directors is a common practice across the biotechnology industry.
- The specific terms of the options, such as the exercise price and vesting schedule, are generally aligned with industry norms for companies of similar size and stage of development.
- Companies like Amgen, Gilead, and Regeneron also use stock options as part of their director compensation packages, although the specific amounts and terms may vary based on company performance and market conditions.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign of aligning director interests with company performance.
- The grant does not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 01/06/2021 | Options to purchase 5,000 shares at $32.10 were granted. |
| 06/30/2021 | Options to purchase 10,000 shares at $30.30 were granted. |
| 06/30/2022 | Options to purchase 10,000 shares at $7.45 were granted. |
| 12/07/2018 | Warrants to purchase 2,105 shares at $57 and 1,667 shares at $60 were granted. |
| 05/22/2019 | Options to purchase 833 shares at $66 were granted. |
| 10/16/2017 | Options to purchase 833 shares at $9 were granted. |
| 06/30/2023 | Options to purchase 10,000 shares at $5.88 were granted. |
| 06/30/2024 | Options to purchase 10,000 shares at $2.37 and 3,018 shares at $2.37 were granted. |
| 09/30/2024 | Options to purchase 3,858 shares at $1.30 were granted. |
| 01/20/2025 | Options to purchase 3,030 shares at $2.33 were granted in lieu of cash compensation. |
| 01/21/2025 | Form 4 filing date. |
Keywords
stock options, director compensation, Lixte Biotechnology, Form 4, insider trading, Stephen Forman, equity securities, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.